Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex™ Did Not Achieve its Primary Endpoint

Business Wire May 1, 2017

Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex™

Business Wire April 28, 2017

Aeterna Zentaris Announces Replacement At the Market Issuance Program

Business Wire April 27, 2017

Aeterna Zentaris Mails Management Information Circular in Connection with Annual Meeting of Shareholders

Business Wire April 3, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  March 30, 2017

Aeterna Zentaris Intends to File NDA with Respect to Macrilen™ in Third Quarter of 2017

Business Wire March 30, 2017

Aeterna Zentaris Announces At the Market Issuance Program

Business Wire March 28, 2017

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results

Business Wire March 15, 2017

Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen™

Business Wire March 7, 2017

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2016 Financial and Operating Results on March 15, 2017

Business Wire March 6, 2017

Aeterna Zentaris Announces Presentation Regarding Macrilen™ at 99th Annual Meeting of the Endocrine Society

Business Wire March 2, 2017

25 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  February 15, 2017

Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium

Business Wire February 14, 2017

Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™

Business Wire February 13, 2017

Aeterna Zentaris to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

Business Wire February 9, 2017

Aeterna Zentaris to Present at the 2017 BIO CEO and Investor Conference

Business Wire February 7, 2017

Research Reports Coverage on Biotech Stocks -- Intercept Pharma, Aeterna Zentaris, Spark Therapeutics, and Aratana Therapeutics

PR Newswire February 1, 2017

15 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  January 31, 2017

Mid-Day Market Update: Dow Falls Over 100 Points; DryShips Shares Spike Higher

Benzinga.com  January 31, 2017

Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017

Business Wire January 30, 2017